Xiaoliang Jin is a Senior Advisor in Clinical Research at Eli Lilly China. He holds a PhD in Pharmacokinetics and has over seven years of industry experience as a clinical pharmacologist across local pharma and biotech in China. His work spans small molecules, biologics, ADCs, and gene editing programs across oncology and non-oncology areas. Jin specialises in model-informed drug development (MIDD), with a focus on supporting first-in-human dose selection and clinical pharmacology strategy.